Acute care Flashcards
Adverse effects of opioids (GOBS SC)
GI slowing - constipation, urinary retention
Opioid induced respiratory depression (with increased CO2 and possibly raised ICP)
Bradycardia
Strong addictive potential
Seizure threshold reduced
CNS depression (intensifies w benzo’s, alcohol)
Effects of opioids (AG)
Analgesia
GI slowing
Opioid receptor full agonists (MMM FC)
Morphine
Methadone
Meperidine
Codeine
Fentanyl
Opioid receptor partial agonist (B)
Buprenorphine
Opioid receptor full antagonists (NNM)
Naloxone
Naltrexone
Methylnaltrexone
Difference between naloxone and naltrexone and clinical use
Naloxone - rapid action, short acting (half life 30-90mins, PO, IM, IV, SC, IO, intranasal)
Naltrexone - long acting (half life 4-10hrs, PO, IM)
Naltrexone used once detoxified to prevent opioid dependence relapse
What is malignant hypothermia?
A subclinical myopathy - general anaesthesia triggers and uncontrollable contraction of skeletal muscle that leads to a life-threatening hypercatabolic state and an increase in body temperature
It is primarily autosomal dominant - mutations in receptors predispose to volatile anaesthetic agents or succinylcholine causing an accumulation of intracellular calcium in skeletal muscle that leads to its overactivation and hypermetabolism.
In acute setting - clinical diagnosis, increase in end-tidal CO2
What is the treatment for malignant hypertension?
Dantrolene (ryanodine receptor antagonist - prevents release of calcium from the sarcoplasmic reticulum of striated muscle - reduced muscle rigidity and hyperthermia)
Clinical presentation of DKA (DANK DF)
Delirium/psychosis
Abdominal pain
Nausea/vomiting
Kussmaul breathing
Dehydration
Fruity (acetone) breath
Clinical presentation of HHS (DPP LFS)
Dehydration (profound)
Polydipsia
Polyuria
Lethargy
Focal neurological deficits
Seizures
Diagnosis of DKA
Hyperglycemia
Anion gap metabolic acidosis (inc hydrogen ions, decreased HCO3)
Normal or increased serum K+ (decreased intracellular K+)
Hyperketonuria
Leukocytosis
No insulin
Diagnosis of HHS
Elderly more susceptible
Insulin present
Hyperglycemia
Normal or increased serum K+ (decreased intracellular K+)
Normal serum pH and ketones
Complications of DKA (CCHM)
Cerebral odema
Cardiac arrhythmias
Heart failure
Mucormycosis
Complications of HHS (CD)
Coma
Death
Treatment of DKA
Fluid resuscitation
Short acting IV insulin
Replacement of potassium
Glucose supplementation if needed
Treatment of HHS
Treatment of hyperkalemia
- Discontinue exogenous sources of potassium
- Treat reversible causes
- Calcium gluconate (stabilises cardiac membrane)
- Calcium chloride (only given in central venous lines as irritating to peripheral vessels)
- Insulin and glucose (usually 10 units of regular insulin given with 50ml of a 50% dextrose solution)
- B2 adrenergic agents (such as albuterol) will also shift potassium intracellularly - usually given at much higher doses than commonly used for bronchodilation
- Loop or thiazide diuretics may help enhance potassium excretion